{'fraction_non_alphanumeric': 0.024549918166939442, 'fraction_numerical': 0.01309328968903437, 'mean_word_length': 6.0344827586206895, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The predictive values of beta1‐adrenergic and M2 muscarinic receptor autoantibodies for sudden cardiac death in patients with chronic heart failure

Clinical and animal studies suggest that beta1‐adrenergic and M2 muscarinic receptor autoantibodies (beta1‐AAbs and M2‐AAbs) play important roles in the pathophysiological process of chronic heart failure (CHF). Removal of these autoantibodies improved haemodynamic parameters and left ventricular ejection fraction patients with CHF. The goal of this project is to evaluate whether beta1‐AAbs and M2‐AAbs predict prognosis and sudden cardiac death (SCD) in CHF.